FEDERAL COURT OF AUSTRALIA
Apotex Pty Ltd v ICOS Corporation (No 3) [2018] FCA 1204
File number: VID 280 of 2016 Judge: BESANKO J Date of judgment: 14 August 2018 Catchwords: PATENTS – where applicant seeks relief by way of declarations of invalidity and orders for revocation of claims in two patents (the 946 Patent and the 666 Patent) – where respondent is the registered owner of the two patents and denies that the claims are invalid – whether, in respect of the 946 Patent, there is a lack of inventive step, lack of novelty, the patent was obtained by false suggestion and the invention is not useful – whether, in respect of the 666 Patent, there is a lack of inventive step and a lack of novelty
PATENTS – where respondent brings a cross-claim against the applicant in which it seeks declarations to the effect that the applicant has threatened to infringe claims in the two patents – whether applicant has threatened to infringe claims in the two patents – where claims in respect of which the respondent alleges threatened infringement are the same claims which the applicant alleges are invalid – where, in respect of the two patents, the applicant admits, subject to its case on invalidity, threatened infringement in respect of certain claims – where applicant denies infringement in respect of certain claims in the two patents – where, in respect of the 666 Patent, the applicant does not admit threatened infringement of certain claims, but accepts that expert evidence establishes threatened infringement, subject to its case on invalidity
PRACTICE AND PROCEDURE – where respondent seeks injunctions, damages or an account of profits, additional damages or other relief – where issues of quantum arising from the respondent’s cross-claim be heard and determined separately from, and after, all other issues in the proceeding
Legislation: Patents Act 1952 (Cth) s 100
Patents Act 1990 (Cth) ss 7, 12, 13, 18, 102, 105, 138
Federal Court Rules 2011 (Cth) r 30.01
Patents Regulations 1991 (Cth) reg 3.12
Cases cited: Actavis Group Ptc EHF v ICOS Corporation [2016] EWHC 1955 (Pat)
Actavis Pty Ltd v Orion Corporation [2016] FCAFC 121
Aktiebolaget Hässle v Alphapharm Pty Ltd [2002] HCA 59; (2002) 212 CLR 411
Alcatel NV v Commissioner of Patents (1996) AIPC 91-260; (1996) 68 FCR 8
Alphapharm Pty Ltd v H Lundbeck A/S [2008] FCA 559; (2008) 76 IPR 618
Anaesthetic Supplies Pty Ltd v Rescare Ltd (1994) AIPC 91-076; (1994) 50 FCR 1
Apotex Pty Ltd v ICOS Corporation [2017] FCA 466
Apotex Pty Ltd v Warner‑Lambert Company LLC (No 2) [2016] FCA 1238; (2016) 122 IPR 17
AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99; (2014) 226 FCR 324
AstraZeneca AB v Apotex Pty Ltd [2015] HCA 30; (2015) 257 CLR 356
Beecham Group Limited v Bristol Laboratories Limited and Another (1978) RPC 153
Beecham Group Ltd’s (Amoxycillin) Application (1980) 97 RCP 261
CCOM Pty Ltd v Jiejing Pty Ltd (1994) AIPC 91-079;…
Keep reading for free
Create a free CaseChat account to read Apotex Pty Ltd v ICOS Corporation (No 3) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2018] FCA 1204
- Decision Date
CaseChat Overview and Summary
The court found that Apotex had threatened to infringe all of the claims in suit in both the 946 Patent and the 666 Patent. While Apotex admitted to threatened infringement of certain claims in both patents, subject to its case on invalidity, it denied infringement in respect of other claims. Regarding the 666 Patent, Apotex did not admit threatened infringement of certain claims but accepted that expert evidence established threatened infringement, subject to its case on invalidity. The court rejected Apotex’s challenge to the validity of the patents, finding that ICOS had established that Apotex threatened to infringe the claims in suit in each patent. The issues of quantum arising from ICOS’s cross-claim were to be heard and determined separately from, and after, all other issues in the proceeding.
The court concluded that Apotex’s challenge to the validity of the 946 Patent and the 666 Patent must be rejected. ICOS had established that Apotex threatened to infringe the claims in suit in each patent. The court directed the respondent to bring in draft minutes of order reflecting the conclusions in these reasons. The entry of orders was to be dealt with in Rule 39.32 of the Federal Court Rules 2011.
Orders
Orders of the court
1. The respondent bring in draft minutes of order reflecting the conclusions in these reasons.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.